Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma

Neuro-Oncology

Volumn 10, Issue 5, 2008, Pages 675-689

  Ridley, Lee ^a   Rahman, Ruman ^a   Brundler, Marie Anne ^b   Ellison, David ^c   Lowe, James ^a,e   Robson, Keith ^a,e   Prebble, Emma ^d   Luckett, Inga ^c   Gilbertson, Richard J ^c   Parkes, Sheila ^b   Rand, Vikki ^a   Coyle, Beth ^a   Grundy, Richard G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Ependymoma; Nucleolin; Pediatric; Telomerase; Telomere

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; KI 67 ANTIGEN; NUCLEOLIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; PHOSPHOPROTEIN; RNA BINDING PROTEIN; TELOMERASE; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; EPENDYMOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACRANIAL TUMOR; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; TELOMERE; TISSUE MICROARRAY; ADOLESCENT; BIOSYNTHESIS; BRAIN TUMOR; CHILD; FLUORESCENCE IN SITU HYBRIDIZATION; INFANT; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PRESCHOOL CHILD;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; EPENDYMOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; PHOSPHOPROTEINS; PROGNOSIS; RNA-BINDING PROTEINS; TELOMERASE; TELOMERE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 56149086808     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-036     Document Type: Article

References (66)

1. Goldwein JW, Leahy JM, Packer RJ, Sutton LN, Curran WJ, Rorke LB, et al. Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys. 1990;19:1497-1502.
2. Akyuz C, Emir S, Akalan N, Soylemezoglu F, Kutluk T, Buyukpamukcu M. Intracranial ependymomas in childhood-a retrospective review of sixty-two children. Acta Oncol (Stockholm). 2000;39:97-100.
3. Grill J, Le Deley MC, Gambarelli D, Raquin MA, Couanet D, Pierre-Kahn A, et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol. 2001;19:1288-1296.
4. Duffner PK, Horowitz ME, Krischer JP, Friedman HS, Burger PC, Cohen ME, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. NEJM. 1993;328:1725-1731.
5. Merchant TE, Mulhern RK, Krasin MJ, Kun LE, Williams T, Li C, et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol. 2004;22:3156-3162.
6. Geyer JR, Sposto R, Jennings M, Boyett JM, Axtell RA, Breiger D, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23:7621-7631.
7. Geyer JR, Zeltzer PM, Boyett JM, Rorke LB, Stanley P, Albright AL, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Children's Cancer Group. J Clin Oncol. 1994;12:1607-1615.
8. Rogers L, Pueschel J, Spetzler R, Shapiro W, Coons S, Thomas T, et al. Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg. 2005;102:629-636.
9. Copeland DR, deMoor C, Moore BD, 3rd, Ater JL. Neurocognitive development of children after a cerebellar tumor in infancy: a longitudinal study. J Clin Oncol. 1999;17:3476-3486.
10. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neu-rocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol. 2004;5:399-408.
11. Riva D, Giorgi C. The neurodevelopmental price of survival in children with malignant brain tumours. Childs Nerv Syst. 2000;16:751-754.
12. Spiegler BJ, Bouffet E, Greenberg ML, Rutka JT, Mabbott DJ. Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol. 2004;22:706-713.
13. Duffner PK. Diagnosis of brain tumors in children. Expert Rev Neu-rother. 2007;7:875-885.
14. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22:984-993.
15. Wiestler O, Schiffer D, Coons S, Prayson R, Rosenblum MK. Ependymoma. In: P Kleihues WC, Cavenee WK, eds. Pathology and Genetics of Tumours of the Nervous System. Lyon, France: International Agency for Research on Cancer; 2000:71-81.
16. Korshunov A, Golanov A, Sycheva R, Timirgaz V. The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era: an analysis of 258 patients. Cancer. 2004;100:1230-1237.
17. Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gam-barelli D, Gentet JC, et al. Prognostic factors in intracranial ependymomas in children. J Neurosurg. 2000;93:605-613.
18. Horn B, Heideman R, Geyer R, Pollack I, Packer R, Goldwein J, et al. A multi-institutional retrospective study of intracranial ependymoma in children: identification of risk factors. J Pediatr Hematol Oncol. 1999;21:203-211.
19. Perilongo G, Massimino M, Sotti G, Belfontali T, Masiero L, Rigobello L, et al. Analyses of prognostic factors in a retrospective review of 92 children with ependymoma: Italian Pediatric Neuro-oncology Group. Med Pediatr Oncol. 1997;29:79-85.
20. Pollack IF, Gerszten PC, Martinez AJ, Lo KH, Shultz B, Albright AL, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. Neurosurgery. 1995;37:655-667.
21. Robertson PL, Zeltzer PM, Boyett JM, Rorke LB, Allen JC, Geyer JR, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg. 1998;88:695-703.
22. Sutton LN, Goldwein J, Perilongo G, Lang B, Schut L, Rorke L, et al. Prognostic factors in childhood ependymomas. Pediatr Neurosurg. 1990;16:57-65.
23. Wolfsberger S, Fischer I, Hoftberger R, Birner P, Slavc I, Dieckmann K, et al. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol. 2004;28:914-920.
24. Verstegen MJ, Leenstra DT, Ijlst-Keizers H, Bosch DA. Proliferation-and apoptosis-related proteins in intracranial ependymomas: an immunohistochemical analysis. J Neurooncol. 2002;56:21-28.
25. Prayson RA. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol. 1999;3:11-18.
26. Ritter AM, Hess KR, McLendon RE, Langford LA. Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1998;40:51-57.
27. Zamecnik J, Snuderl M, Eckschlager T, Chanova M, Hladikova M, Tichy M, et al. Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol. 2003;16:980-991.
28. Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res. 2002;8:3054-3064.
29. Bennetto L, Foreman N, Harding B, Hayward R, Ironside J, Love S, et al. Ki-67 immunolabelling index is a prognostic indicator in childhood posterior fossa ependymomas. Neuropathol Appl Neurobiol. 1998;24:434-440.
30. Lens SM, Vader G, Medema RH. The case for survivin as mitotic regulator. Curr Opin Cell Biol. 2006;18:616-622.
31. Altura RA, Olshefski RS, Jiang Y, Boue DR. Nuclear expression of sur-vivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Br J Cancer. 2003;89:1743-1749.
32. Preusser M, Wolfsberger S, Czech T, Slavc I, Budka H, Hainfellner JA. Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol. 2005;124:543-549.
33. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nature Rev. 2001 ;2:127-137.
34. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:21-26.
35. Tabori U, Ma J, Carter M, Zielenska M, Rutka J, Bouffet E, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol. 2006;24:1522-1528.
36. Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci. 2006;119:2797-2806.
37. Grinstein E, Wernet P. Cellular signaling in normal and cancerous stem cells. Cell Signal. 2007;19:2428-2433.
38. Srivastava M, Pollard HB. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J. 1999; 13:1911-1922.
39. Grundy RG, Wilne SA, Weston CL, Robinson K, Lashford LS, Ironside J, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol. 2007;8:696-705.
40. Bouffet E, Tabori U, Bartels U. Paediatric ependymomas: should we avoid radiotherapy? Lancet Oncol. 2007;8:665-666.
41. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
42. Grinstein E, Shan Y, Karawajew L, Snijders PJ, Meijer CJ, Royer HD, et al. Cell cycle-controlled interaction of nucleolin with the retinoblastoma protein and cancerous cell transformation. J Biol Chem. 2006;281:22223-22235.
43. Ginisty H, Sicard H, Roger B, Bouvet P. Structure and functions of nucleolin. J Cell Sci. 1999;112(pt 6): 761-772.
44. Khurts S, Masutomi K, Delgermaa L, Arai K, Oishi N, Mizuno H, et al. Nucleolin interacts with telomerase. J Biol Chem. 2004;279:51508-51515.
45. Ishikawa F, Matunis MJ, Dreyfuss G, Cech TR. Nuclear proteins that bind the pre-mRNA 3' splice site sequence r(UUAG/G) and the human telomeric DNA sequence d(TTAGGG)n. Mol Cell Biol. 1993;13:4301-4310.
46. Pollice A, Zibella MP, Bilaud T, Laroche T, Pulitzer JF, Gilson E. In vitro binding of nucleolin to double-stranded telomeric DNA. Biochem Bio-phys Res Commun. 2000;268:909-915.
47. Derenzini M, Sirri V, Trere D, Ochs RL. The quantity of nucleolar proteins nucleolin and protein B23 is related to cell doubling time in human cancer cells. Lab Invest. 1995;73:497-502.
48. Derenzini M. The AgNORs. Micron. 2000;31:117-120.
49. Ugrinova I, Monier K, Ivaldi C, Thiry M, Storck S, Mongelard F, et al. Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol. 2007;8:66.
50. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787-791.
51. Bryan TM, Cech TR. Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol. 1999;11:318-324.
52. Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 2003;361:836-838.
53. Poremba C, Scheel C, Hero B, Christiansen H, Schaefer KL, Nakayama J, et al. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol. 2000;18:2582-2592.
54. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 2004;22:3790-3797.
55. Didiano D, Shalaby T, Lang D, Grotzer MA. Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-Oncology. 2004;6:1-8.
56. Tabori U, Vukovic B, Zielenska M, Hawkins C, Braude I, Rutka J, et al. The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. Neoplasia. 2006;8:136-142.
57. Morii K, Tanaka R, Onda K, Tsumanuma I, Yoshimura J. Expression of telomerase RNA, telomerase activity, and telomere length in human gliomas. Biochem Biophys Res Commun. 1997;239:830-834.
58. Cong YS, Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem. 2000;275:35665-35668.
59. Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. Cancer Res. 2000;60:537-541.
60. Armanios M, Greider CW. Telomerase and cancer stem cells. Cold Spring Harbor Symp Quant Biol. 2005;70:205-208.
61. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133: 1710-1715.
62. Suzuki S, Oka H, Kawano N, Tanaka S, Utsuki S, Fujii K. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas. Brain Tumor Pathol. 2001 ;18:151-154.
63. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Sur-vivin: a promising tumor biomarker. Cancer Lett. 2007;249:49-60.
64. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67:5999-6002.
65. Mendrzyk F, Korshunov A, Benner A, Toedt G, Pfister S, Radlwimmer B, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res. 2006;12:2070-2079.
66. Gilbertson RJ. ERBB2 in pediatric cancer: innocent until proven guilty. Oncologist. 2005;10:508-517.